The Spanish SOLTI-1716 TATEN trial sees favourable responses and survival when combining pembrolizumab and paclitaxel in HER2-enriched or basal-like tumours....
An ESTRO expert panel reviews 27 phase I and phase II studies on radiotherapy before surgery in breast cancer and sets out its future perspectives....
A phase IIa trial evaluates ceralasertib, an oral ATR inhibitor, in advanced tumours with ATM alterations. Objective responses were limited, although the safety profile was manageable....
A Spanish pilot study reports five-year results of a hypofractionated chemoradiotherapy strategy before surgery in HER2-positive and triple-negative breast cancer....
A genomic analysis of the NeoTRIPaPDL1 trial identifies tumour features and early changes during treatment associated with response to neoadjuvant chemoimmunotherapy....
An updated review covers the evidence on the HER2DX genomic test to individualise treatment intensity in early-stage HER2-positive breast cancer....
The PERUSE study confirms in 1,436 patients with advanced HER2-positive breast cancer a median overall survival of more than five years with pertuzumab and trastuzumab plus a taxane....
A phase I/II trial evaluates the first conditionally activated antibody-drug conjugate against CD166, with clinical and translational activity across several tumour types, including breast cancer....
A panel of experts from 11 Spanish-speaking countries publishes the first recommendations tailored to Latin American resources for early-stage hormone receptor-positive, HER2-negative breast cancer....
In the phase III PEARL trial, combining palbociclib with endocrine therapy did not improve progression-free survival versus capecitabine, although it offered a better safety profile and quality of lif...